RxSight, Inc. (RXST)
NASDAQ: RXST · Real-Time Price · USD
11.42
-0.10 (-0.87%)
At close: Nov 28, 2025, 1:00 PM EST
11.26
-0.16 (-1.40%)
After-hours: Nov 28, 2025, 4:48 PM EST
RxSight Revenue
RxSight had revenue of $30.34M in the quarter ending September 30, 2025, a decrease of -14.09%. This brings the company's revenue in the last twelve months to $142.09M, up 10.75% year-over-year. In the year 2024, RxSight had annual revenue of $139.93M with 57.09% growth.
Revenue (ttm)
$142.09M
Revenue Growth
+10.75%
P/S Ratio
3.27
Revenue / Employee
$285,311
Employees
498
Market Cap
469.55M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 139.93M | 50.85M | 57.09% |
| Dec 31, 2023 | 89.08M | 40.07M | 81.77% |
| Dec 31, 2022 | 49.01M | 26.41M | 116.90% |
| Dec 31, 2021 | 22.59M | 7.92M | 53.92% |
| Dec 31, 2020 | 14.68M | 12.44M | 554.98% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2006 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2005 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2004 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2003 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
RXST News
- 9 days ago - RxSight, Inc. to Present at the Piper Sandler Healthcare Conference - GlobeNewsWire
- 24 days ago - RxSight, Inc. (RXST) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 24 days ago - RxSight, Inc. Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - RxSight, Inc. to Report Third Quarter 2025 Financial Results on November 5, 2025 - GlobeNewsWire
- 6 weeks ago - RxSight, Inc. to Feature Live Learning Sessions at American Academy of Ophthalmology 2025 Annual Meeting - GlobeNewsWire
- 2 months ago - The Bottom Fishing Club - RxSight: A Ski-Jump Reversal Pattern? - Seeking Alpha
- 2 months ago - RxSight, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - RXST - PRNewsWire
- 2 months ago - SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RxSight - GlobeNewsWire